Bob joined HMC in September 2008 and serves as a Board Member of Optimal Radiology, WellCentive, and RegisterPatient. He also serves as a board observer for Innovative Biosensors, MaxCyte, OpenQ and CliniPace. In addition to his responsibilities at HMC, he serves as the President-elect of the Southeastern Medical Device Association, Chairman of the Commercialization Sub-Committee for the Birmingham Business Alliance’s Economic Prosperity Committee, a member of the Steering Committee of the Alabama Obesity Institute at the University of Alabama in Birmingham, a member of the investor advisory boards for the Florida High Tech Corridor Council and the Florida Institute for the Commercialization of Public Research. He is a Venture Fellow at the University of Alabama in Tuscaloosa, is a Visiting Executive at Auburn University and is a member of the Board of Directors for the Birmingham Venture Club and the Atlanta Venture Forum. Prior to joining HVP, Mr. Crutchfield served as Senior Vice President/General Manager of the Pharmacy Services Division at U.S. Oncology, a privately held, vertically integrated cancer care provider network. The division was responsible for approximately $2 billion of annual revenue, and under his leadership the division’s EBITDA grew to over $80 million. Bob was also a Senior Executive at Cardinal Health, where he served as Vice President of New Ventures. While with Cardinal Health, he built and launched a new surgical products business unit through licensing of new technologies and the acquisition of Snowden Pencer Instrument Company. In 1994, Bob founded Surgical Innovations and Services, Inc. (SIS), a surgical laser management company. Under his leadership, SIS became a leader in the emerging outsource management sector, with over 300 hospitals and surgery centers under contract with SIS for management oversight and delivery of their surgical laser programs. In 2000, SIS merged with Surgical Laser Technologies, Inc. (SLTI) a publicly traded surgical laser-manufacturing firm. He continued as President of SIS and served as VP of Sales, Marketing and Business Development for SLTI until he exited the company following its acquisition by publicly-traded Photomedex, Inc. Bob has launched five successful new business ventures during his private and corporate career and has led four M&A transactions. He is a graduate of the University of Georgia and holds Bachelor of Science degrees in Political Science and Chemistry.

David Hartnett is the vice president of bioscience and health IT industry development for Metro Atlanta Chamber’s economic development division. Prior to joining the Chamber, Hartnett served as the president and CEO of Maco Pharma (formerly United Pharma) a privately held medical device/pharmaceutical company based in Duluth, Georgia, headquartered in Lille France. Prior to Maco Pharma, Hartnett was president and CEO of SteriFx Corporation, a specialty chemical company, contracted by U.S. Department of Defense (DARPA). Prior to SteriFx, he was the executive vice president of the North American headquarters of Given Imaging, Inc. Under his leadership the company commercialized the “PillCam” video capsule, a disposable capsule that captures video after it is ingested by the patient. Hartnett helped to raise more than $30 million in a private placement for corporate infrastructure development and product commercialization prior to the company going public in 2001 (GIVN-NASDAQ). Hartnett served as vice president of marketing at ERBE Electrosurgery, the largest manufacturer of electrosurgical systems in the world, where he was responsible for commercial marketing throughout North America. He has also served in a variety of other senior sales and marketing roles for the following companies: Karl Storz Lithotripsy, Genzyme (formerly Deknatel), STERIS (formerly AMSCO) and the XEROX Corporation. He holds a B.A. in speech communication from San Diego State University with a master’s equivalent in marketing through post-graduate studies. He currently serves on the following boards:

Linda Braddon, Ph.D., President, Secure BioMed Evaluations (SecureBME) works with medical device companies providing technical solutions to regulatory problems. SecureBME helps companies bring their medical device to market faster by helping companies assess clinical risks, design and execute non-clinical testing, prepare regulatory submissions, maintain technical files for CE marking and respond to deficiency letters from FDA. Dr. Braddon's professional experience includes extensive work with devices in areas of orthopaedics, dental implants, ophthalmology, respiratory, urology, hydrogels and antimicrobial agents. She is the co-inventor of a U.S. patent for an orthopaedic device that is CE marked and is currently going through the FDA approval process. She is an active member of the North American Spinal Society, American Standards for Testing and Materials, and the Southeastern Medical Device Association. Dr. Braddon holds a bachelor of science in Engineering from Mercer University along with a master’s and a Ph.D. in mechanical engineering with a specialization in bioengineering from Georgia Institute of Technology.

Mr. Davis is a seasoned medical device executive with broad global and functional experience in finance, manufacturing, sales and general management. He is currently the Founder & CEO of The MedCelerate Consulting Group (www.medcelerate.com). MedCelerate enables medical device companies to grow and succeed in international markets at a faster velocity. The practice focuses on early assessment of international opportunities through full manufacturing and commercial ramp-up activities. Prior to founding MedCelerate, Mr. Davis was CEO of Tryton Medical, a ventured-backed, coronary stent, start-up company. During his tenure at Tryton he raised $20 million in Series D financing and initiated enrollment in the company’s groundbreaking U.S. pivotal trial. Mr. Davis also launched the company’s Side Branch Stent across Europe where it quickly became the established market leader. Prior to joining Tryton, Mr. Davis was president of Guidant Japan with P&L responsibility for the company’s $225 million cardiovascular business. Prior to his work in Japan, Mr. Davis managed Guidant’s product portfolio in 13 Asian countries. He was also instrumental in the start up and management of a FDA-regulated, Class III manufacturing facility in Dorado, Puerto Rico. Mr. Davis started his career in various financial management roles with Cardiac Pacemakers Incorporated and Eli Lilly in the U.S. and Puerto Rico. Mr. Davis holds a B.S. in mechanical engineering from the University of Minnesota and an M.B.A. from the University of Michigan. Mr. Davis is the Chairman of the Board for ibiliti (www.ibiliti-nc.com), a non-profit organization created to accelerate the growth and commercialization of advanced medical technologies in North Carolina.

With 24 years of diverse, entrepreneurial business, and healthcare experience, Paul has a proven track record of delivering results. Senior leadership positions he has held include Founder, CEO, President, Board of Directors, COO and EVP. Paul’s background also includes numerous start-ups, turnarounds, roll-ups, integration of acquired companies, multi-site and state operations, public, private and venture backed financing's, medical devices, clinical and patient care services, international recruiting & staffing, developing numerous strategic alliances, education and completing over 20 M&A transactions with a combined value in excess of $100 million. As president of PJ Fitzpatrick Executive Advisory Group, LLC, Paul provides interim and fractional CEO and Board engagements and advisory services to start-ups, early stage and small healthcare services and medical device companies. Among others, Paul serves as CEO and Director of Advanced Catheter Therapies, Inc., (ACT) in Chattanooga, TN, with responsibility for developing and executing the Company’s business model, strategy and raising $3M of capital. He also serves as a Non-Executive Director and Executive Advisor at QuantuMDx Group Limited, a UK-based early stage R&D medical device company. Paul has served as interim Chief Executive Officer and director of NeoMatrix, LLC and as a consultant with Waveland Capital Group LLC where he monitored Waveland Capital Partners’ portfolio companies. In 2002, he founded and served as President and CEO of I-Medical Staffing, a U.S. based healthcare staffing company that sourced, prepared, and employed highly experienced internationally trained, English-speaking registered nurses for assignments into U.S. healthcare facilities; he executed its merger in 2006 with a large domestic staffing company. Prior to that, Paul was the Executive Vice President and COO and a start-up team member of Healthcare Innovations, Inc., a rehabilitation services company, where he was responsible for mergers and acquisitions and operations. Paul was responsible for and orchestrated its sale in 2001 to a large publicly traded company. From 1994 to 1997, Paul was a Corporate Vice President at Careline, Inc., an emergency medical services rollup company, which had two public offerings raising $160 million, and was eventually acquired for $358 million. His responsibilities included acquisition due diligence, strategic planning and integration. Prior to that, Paul was founder and president of P.J. Fitzpatrick & Associates, Inc., an emergency medical services consulting firm. Paul is a graduate of the Daniel Freeman Hospital Paramedic School, earning his board certification as a National Registered Paramedic, and holds a degree in paramedic technology from Northeastern University in Boston, where he served as an adjunct faculty member for 10 years.

Paul Gianneschi is the Managing Principal and Founder of Hatch Medical, L.L.C., a privately held medical device incubator and technology brokerage firm focused on assisting physician inventors, entrepreneurs and early-stage companies with the commercialization of minimally invasive medical device technologies. Mr. Gianneschi has spent the past 21 years as an executive in the healthcare industry. Prior to founding Hatch Medical in 2000, Mr. Gianneschi served over seven years in a series of senior level marketing and sales management positions with medical device industry leader, C. R. Bard, Inc.'s Peripheral Vascular Division. Prior to joining Bard, Mr. Gianneschi worked in similar capacities with Bausch & Lomb and NDC Health / McKesson. Mr. Gianneschi earned a Bachelor of Science degree from the University of Florida and an Executive M.B.A. in International Management from Mercer University, where he currently serves on their business school’s Board of Visitors and Alumni Board. Mr. Gianneschi is also a board member of Piedmont Healthcare and Mercer University’s joint Center for Health and Learning. Mr. Gianneschi is a past-president and current board member of the Southeastern Medical Device Association and also serves on the American – Israel Chamber of Commerce, SE Region – Medical Committee.

Chris Lepore is the Senior Director of State Government Affairs for Johnson & Johnson, managing the Corporation’s state legislative and regulatory team in 10 Southern states, the District of Columbia, and Puerto Rico. Chris serves as Chair of Georgia Bio’s Government Affairs Committee, and Vice Chair of PhRMA’s Georgia Task Force. He joined Johnson & Johnson in 2004. He brings with him a strong government affairs background having 19 years of legislative and regulatory experience. Before joining Johnson & Johnson he was Manager of State Government Affairs for Schering-Plough Corporation, where he was responsible for the corporation's lobbying efforts in Arizona, Colorado, New Mexico, Utah, and Wyoming. Lepore is a graduate of the University of Northern Colorado where he received a Bachelor of Arts Degree in Communications. Johnson & Johnson, through its operating companies, is the world's most comprehensive and broadly based manufacturer of health care products.

Thomas Looby has served as Senior Vice President and Chief Marketing Officer since July 2010. Prior to that, from September 2006 until July 2010, he has served Given Imaging in various roles including the Vice President of Corporate Strategy and Planning and Director of Upper GI Products. Before joining Given Imaging, from January 2001 until September 2006, Mr. Looby worked for Eastman Kodak and Scitex Digital Printing as Director of Global Product Marketing and Business Strategy. Additionally, Mr. Looby has worked for Bayer, Chemineer and Giddings & Lewis in a variety of marketing and business management roles. Mr. Looby graduated with a B.S. in Chemical Engineering from the University of Notre Dame and holds an MBA from the University of Dayton.

Tom is the CEO of Claro Scientific, a diagnostic company focused on commercializing an innovative optics-based analytical system for research, manufacturing and medical applications. Claro is located in St. Petersburg, FL. Previously he held several executive leadership roles in the biotechnology, pharmaceutical and consumer products industries. From 1998 through 2007, he worked at Nabi Biopharmaceuticals, a NASDAQ listed life sciences company developing and marketing vaccine and antibody products. His positions included Chief Executive Officer and President (2002-2007), Executive Vice President and Chief Operating Officer (2001-2002), and Senior Vice President, Corporate Services and Chief Financial Officer (1998-2002). From 1988 to 1998, Mr. McLain was employed by Bausch & Lomb, Inc., a global eye care company, where he held various executive positions, including Vice President Business Process Reengineering, Assistant Corporate Controller and Vice President Accounting and Financial Reporting. Before joining Bausch & Lomb, Mr. McLain practiced with the accounting firm of Ernst & Young LLP. In addition Tom has served on several corporate and non-profit boards including Eastman Chemical Company (board member, health safety, environment and security committee chair, audit committee and finance committee member), Nabi Biopharmaceuticals (board member and board chairman), SEMDA (board member), BioFlorida (board member, board chairman and legislative affairs committee chair), Biotechnology Industry Organization (health section governing board, regulatory environment committee and reimbursement committee member), Enterprise Development Corporation (board member) and Rochester General Hospital Foundation (board member, vice-chair and treasurer). Tom is a certified public accountant in New York State. He earned his BA in economics at the College of the Holy Cross and his MBA from the William E. Simon Graduate School of Management at the University of Rochester.

Robert Natowitz is the President of Ideal Search Services LLC. His focus is talent acquisition in the medical device field nationwide. He specializes in engineering recruitment, to include product development, R&D, design assurance and quality. Prior to relocating to Atlanta, he spent ten years as partner at DeMatteo Associates, a specialty search firm in Albany, NY. Rob is a member of the American-Israel Chamber of Commerce. He is a volunteer at the Outreach and Advocacy Center which serves the homeless and near-homeless in downtown Atlanta. He received a BA in English from the State University of New York at Potsdam.

David Stern was the first employee of CardioMEMS, Inc., an Atlanta-based medical device company that has developed proprietary wireless sensing and communication technology designed to improve the management of chronic diseases. He is currently an Executive Vice-President and a member of the board of directors. Prior to joining CardioMEMS, David was Vice President and Business Unit Manager of the Peripheral Technologies Division of C.R. Bard. He is a former president and current board member of SEMDA and is Co-Chairman of the Medical Device Committee for Georgia Bio. In addition, he is a member of the Advanced Technology Development Center’s Entrepreneur Advisory Council and Georgia Tech’s Biomedical Engineering Advisory Board. David received degrees in Biomedical Engineering from Rensselaer Polytechnic Institute and Worcester Polytechnic Institute and is the holder of 10 patents.

Rik Vandevenne is a Director with River Cities Capital Funds, where he focuses on information technology and healthcare investment opportunities. Rik is responsible for sourcing and evaluating new investment opportunities and working with executives in portfolio companies on marketing, sales execution, product development and strategy. Prior to his private equity career, Rik gained experience working with venture backed companies in the strategy group of Scient, a global eBusiness consulting firm. Before Scient, Rik worked for four years at Accenture, first in the healthcare services group and then at the Internet Center of Excellence where he helped launch several venture-backed companies as well as worked on the team that developed the online music platform for BestBuy. Rik serves on the boards of ABT Molecular Imaging, EndoChoice and Univa and is an observer at Pioneer Surgical. He was previously on the board of Fullscope, which sold to Edgewater (Nasdaq: EDGW) in 2009. Rik graduated from Vanderbilt University, where he received his BE in Mechanical Engineering, and he received an MBA from Duke University. Rik is on the board of the Center for Entrepreneurial Development (CED), one of the largest entrepreneurial organizations in the country, and is a frequent guest lecturer at Duke University on Entrepreneurship and Venture Capital.